Abstract
Amino acid residues 3-15 of mycobacterial HSP60 define a dominant T-cell epitope for HLA-DR3+ve humans and Mamu-DR3+ve rhesus monkeys. Our results show that Mamu-DR3 molecules on PBMC can be efficiently loaded in vivo with the above-mentioned peptides when they are intravenously injected encapsulated in liposomes, but not in the free form. Mamu-DR3 loading is abolished by encapsulation of a nonstimulatory peptide. These results have implications for the delivery of therapeutic peptides in vivo.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Binding, Competitive / drug effects
-
Binding, Competitive / immunology
-
Drug Carriers
-
Female
-
Histocompatibility Antigens Class II / administration & dosage*
-
Histocompatibility Antigens Class II / drug effects
-
Histocompatibility Antigens Class II / metabolism
-
Injections, Intravenous
-
Liposomes / administration & dosage
-
Liposomes / pharmacology*
-
Lymphocyte Activation / drug effects
-
Macaca mulatta
-
Male
-
Peptides / administration & dosage*
-
Peptides / immunology*
-
Peptides / metabolism
-
Protein Binding / drug effects
-
Protein Binding / immunology
-
T-Lymphocytes / immunology
Substances
-
Drug Carriers
-
Histocompatibility Antigens Class II
-
Liposomes
-
Peptides